LS Investment Advisors LLC boosted its position in LivaNova PLC (NASDAQ:LIVN) by 70.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,840 shares of the company’s stock after buying an additional 1,176 shares during the period. LS Investment Advisors LLC’s holdings in LivaNova PLC were worth $143,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the company. Capstone Asset Management Co. purchased a new stake in shares of LivaNova PLC during the second quarter worth approximately $204,000. AXA purchased a new stake in shares of LivaNova PLC during the first quarter worth approximately $291,000. Algert Global LLC purchased a new stake in shares of LivaNova PLC during the first quarter worth approximately $438,000. UBS Group AG boosted its stake in shares of LivaNova PLC by 15.6% in the first quarter. UBS Group AG now owns 10,520 shares of the company’s stock worth $567,000 after buying an additional 1,418 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of LivaNova PLC by 2,043.9% in the second quarter. BNP Paribas Arbitrage SA now owns 18,845 shares of the company’s stock worth $947,000 after buying an additional 17,966 shares during the last quarter. 63.67% of the stock is currently owned by institutional investors and hedge funds.
Shares of LivaNova PLC (NASDAQ:LIVN) traded up 0.23% on Friday, hitting $60.11. The stock had a trading volume of 413,377 shares. LivaNova PLC has a 12 month low of $46.79 and a 12 month high of $77.00. The stock’s market cap is $2.94 billion. The firm has a 50 day moving average of $60.81 and a 200 day moving average of $54.06.
LIVN has been the topic of a number of analyst reports. WBB Securities reaffirmed a “hold” rating and set a $60.00 price objective on shares of LivaNova PLC in a research note on Wednesday, August 31st. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $70.00 price objective (up previously from $59.00) on shares of LivaNova PLC in a research note on Friday, August 5th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $67.20.
In other LivaNova PLC news, major shareholder Two S.C.A. Equinox sold 25,408 shares of the business’s stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $60.02, for a total value of $1,524,988.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jacques Gutedel sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $60.52, for a total value of $242,080.00. Following the completion of the sale, the insider now owns 10,948 shares of the company’s stock, valued at approximately $662,572.96. The disclosure for this sale can be found here. 0.70% of the stock is owned by company insiders.
LivaNova PLC Company Profile
LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing.
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.